Sumitovant Biopharma Revenue and Competitors

Sumitovant is a global biopharma company with offices in New York and London. It is the parent company of five biopharmaceutical companies: Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and Spirovant Sciences. Our companies have a robust pipeline of innovative drug treatments targeting a broad range of diseases. ￃﾢ￢ﾂﾬￂﾢ Sumitovantￃﾢ￢ﾂﾬ￢ﾄﾢs Digital Innovation approach integrates key skill sets, data sets and analytic tools to provide real answers to pharmaￃﾢ￢ﾂﾬ￢ﾄﾢs most critical questions. With our tech-enabled approach to drug discovery, development and commercialization, we remove friction and accelerate every aspect of the process to bring promising new compounds to market. Sumitovant is wholly owned by Sumitomo Dainippon Pharma. Together, the Sumitomo Dainippon Pharma group of companies closely collaborate to expedite the discovery, development, and commercialization of truly innovative treatments. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes and shareholder return.